Overexpression of miRNA-216 in exosomes derived from umbilical cord mesenchymal stem cells promotes angiogenesis and improves functional recovery after spinal cord injury

Document Type : Original Article

Authors

1 Department of Spine Surgery, Loudi Central Hospital, Loudi, 417000, China

2 Department of Spine Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China

10.22038/ijbms.2025.85963.18571

Abstract

Objective(s): This study aimed to engineer miR-216-overexpressing umbilical cord mesenchymal stem cells (UCMSCs) to generate miR-216-enriched UCMSC-derived exosomes (UCMSC-Exos) and evaluate their therapeutic potential in Spinal cord injury (SCI).
Materials and Methods: miR-216 overexpression was achieved in UCMSCs, and exosomes were subsequently isolated. The biological effects of miR-216-overexpressing UCMSC-Exos (UCMSC-miR-216OE-Exos) were assessed using in vitro migration, and tube formation assays with vascular endothelial cells. For in vivo evaluation, SCI mouse models were treated with either UCMSC-Exos or UCMSC-miR-216OE-Exos. Functional recovery was measured using the BMS scores, while angiogenesis, neuronal apoptosis, and proinflammatory cytokine expression were analyzed through immunohistochemistry and molecular assays.
Results: qPCR analysis confirmed successful miR-216 overexpression in UCMSCs and their derived exosomes. In vitro, UCMSC-miR-216OE-Exos significantly enhanced endothelial cell migration and tube formation compared to control UCMSC-Exos. In vivo, both UCMSC-Exos and UCMSC-miR-216OE-Exos improved BMS scores, promoted angiogenesis, and reduced neuronal apoptosis and proinflammatory cytokine expression in SCI mice. Notably, UCMSC-miR-216OE-Exos demonstrated superior therapeutic effects, including greater improvements in functional recovery, enhanced angiogenic responses, and more pronounced reductions in neuronal apoptosis and inflammation compared to control UCMSC-Exos. Additionally, in vitro experiments revealed that PTEN expression was down-regulated, and the AKT pathway was activated following treatment with UCMSC-miR-216OE-Exos.
Conclusion: These findings demonstrate that miR-216-overexpressing UCMSC-Exos exhibits enhanced therapeutic efficacy in promoting angiogenesis, reducing inflammation and neuronal apoptosis, and improving functional recovery after SCI. This study demonstrates the promise of miR-216-enriched exosomes as a novel cell-free therapeutic approach for SCI, paving the way for clinical translation through their biologically translatable mechanisms.

Keywords

Main Subjects


1. McDonald JW, Sadowsky C. Spinal-cord injury. Lancet 2002; 359: 417-425.
2. Chay W, Kirshblum S. Predicting outcomes after spinal cord injury. Phys Med Rehabil Clin N Am 2020; 31: 331-343.
3. Anjum A, Yazid MD, Fauzi Daud M, Idris J, Ng AMH, Selvi Naicker A, et al. Spinal cord injury: Pathophysiology, multimolecular interactions, and underlying recovery mechanisms. Int J Mol Sci 2020; 21: 7533-7566.
4. Liu WZ, Ma ZJ, Li JR, Kang XW. Mesenchymal stem cell-derived exosomes: Therapeutic opportunities and challenges for spinal cord injury. Stem Cell Res Ther 2021; 12: 102-115.
5. Lankford KL, Arroyo EJ, Nazimek K, Bryniarski K, Askenase PW, Kocsis JD. Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord. PLoS One 2018; 13: e0190358-0190378.
6. Ren Z, Qi Y, Sun S, Tao Y, Shi R. Mesenchymal stem cell-derived exosomes: Hope for spinal cord injury repair. Stem Cells Dev 2020; 29: 1467-1478.
7. Liu W, Rong Y, Wang J, Zhou Z, Ge X, Ji C, et al. Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization. J Neuroinflammation 2020; 17: 47-69.
8. Juni RP, Kocken JMM, Abreu RC, Ottaviani L, Davalan T, Duygu B, et al. MicroRNA-216a is essential for cardiac angiogenesis. Mol Ther 2023; 31: 1807-1828.
9. Ge X, Tang P, Rong Y, Jiang D, Lu X, Ji C, et al. Exosomal miR-155 from M1-polarized macrophages promotes EndoMT and impairs mitochondrial function via activating NF-kappaB signaling pathway in vascular endothelial cells after traumatic spinal cord injury. Redox Biol 2021; 41: 101932-101949.
10. Gao P, Yi J, Chen W, Gu J, Miao S, Wang X, et al. Pericyte-derived exosomal miR-210 improves mitochondrial function and inhibits lipid peroxidation in vascular endothelial cells after traumatic spinal cord injury by activating JAK1/STAT3 signaling pathway. J Nanobiotechnology 2023; 21: 452-470.
11. Xie Y, Sun Y, Liu Y, Zhao J, Liu Q, Xu J, et al. Targeted delivery of RGD-CD146(+)CD271(+) human umbilical cord mesenchymal stem cell-derived exosomes promotes blood-spinal cord barrier repair after spinal cord injury. ACS Nano 2023; 17: 18008-18024.
12. Xiao X, Li W, Xu Z, Sun Z, Ye H, Wu Y, et al. Extracellular vesicles from human umbilical cord mesenchymal stem cells reduce lipopolysaccharide-induced spinal cord injury neuronal apoptosis by mediating miR-29b-3p/PTEN. Connect Tissue Res 2022; 63: 634-649.
13. Ni S, Luo Z, Jiang L, Guo Z, Li P, Xu X, et al. UTX/KDM6A deletion promotes recovery of spinal cord injury by epigenetically regulating vascular regeneration. Mol Ther 2019; 27: 2134-2146.
14. Sheng X, Zhao J, Li M, Xu Y, Zhou Y, Xu J, et al. Bone marrow mesenchymal stem cell-derived exosomes accelerate functional recovery after spinal cord injury by promoting the phagocytosis of macrophages to clean myelin debris. Front Cell Dev Biol 2021; 9: 772205-772224.
15. Guo Z, Li C, Cao Y, Qin T, Jiang L, Xu Y, et al. UTX/KDM6A deletion promotes the recovery of spinal cord injury by epigenetically triggering intrinsic neural regeneration. Mol Ther Methods Clin Dev 2021; 20: 337-349.
16. Xiong W, Li C, Kong G, Zeng Q, Wang S, Yin G, et al. Treg cell-derived exosomes miR-709 attenuates microglia pyroptosis and promotes motor function recovery after spinal cord injury. J Nanobiotechnology 2022; 20: 529-546.
17. Milich LM, Choi JS, Ryan C, Cerqueira SR, Benavides S, Yahn SL, et al. Single-cell analysis of the cellular heterogeneity and interactions in the injured mouse spinal cord. J Exp Med 2021; 218: e20210040-e20210071.
18. Zhang Y, Wang J, Yang B, Qiao R, Li A, Guo H, et al. Transfer of microRNA-216a-5p from exosomes secreted by human urine-derived stem cells reduces renal ischemia/reperfusion injury. Front Cell Dev Biol 2020; 8: 610587-610602.
19. Cheng S, Zhang X, Feng Q, Chen J, Shen L, Yu P, et al. Astragaloside IV exerts angiogenesis and cardioprotection after myocardial infarction via regulating PTEN/PI3K/Akt signaling pathway. Life Sci 2019; 227: 82-93.
20. Han X, Zhang G, Chen G, Wu Y, Xu T, Xu H, et al. Buyang huanwu decoction promotes angiogenesis in myocardial infarction through suppression of PTEN and activation of the PI3K/Akt signalling pathway. J Ethnopharmacol 2022; 287: 114929.
21. Fan B, Wei Z, Yao X, Shi G, Cheng X, Zhou X, et al. Microenvironment imbalance of spinal cord injury. Cell Transplant 2018; 27: 853-866.
22. Ambrozaitis KV, Kontautas E, Spakauskas B, Vaitkaitis D. [Pathophysiology of acute spinal cord injury]. Medicina (Kaunas) 2006; 42: 255-261.
23. Venkatesh K, Ghosh SK, Mullick M, Manivasagam G, Sen D. Spinal cord injury: Pathophysiology, treatment strategies, associated challenges, and future implications. Cell Tissue Res 2019; 377: 125-151.
24. Tsivelekas K, Evangelopoulos DS, Pallis D, Benetos IS, Papadakis SA, Vlamis J, et al. Angiogenesis in spinal cord injury: Progress and treatment. Cureus 2022; 14: e25475-25483.
25. Yao C, Cao X, Yu B. Revascularization after traumatic spinal cord injury. Front Physiol 2021; 12: 631500-63150.
26. Walchli T, Pernet V, Weinmann O, Shiu JY, Guzik-Kornacka A, Decrey G, et al. Nogo-A is a negative regulator of CNS angiogenesis. Proc Natl Acad Sci U S A 2013; 110: E1943-1952.
27. Fassbender JM, Whittemore SR, Hagg T. Targeting microvasculature for neuroprotection after SCI. Neurotherapeutics 2011; 8: 240-251.
28. Shao A, Tu S, Lu J, Zhang J. Crosstalk between stem cell and spinal cord injury: Pathophysiology and treatment strategies. Stem Cell Res Ther 2019; 10: 238-251.
29. Huang L, Fu C, Xiong F, He C, Wei Q. Stem cell therapy for spinal cord injury. Cell Transplant 2021; 30: 963689721989266.
30. Lu Y, Zhang W, Tian Z, Liang Q, Liu C, Wu Y, et al. The optimal transplantation strategy of umbilical cord mesenchymal stem cells in spinal cord injury: A systematic review and network meta-analysis based on animal studies. Stem Cell Res Ther 2022; 13: 441-455.
31. Yao L, He C, Zhao Y, Wang J, Tang M, Li J, et al. Human umbilical cord blood stem cell transplantation for the treatment of chronic spinal cord injury: Electrophysiological changes and long-term efficacy. Neural Regen Res 2013; 8: 397-403.
32. Andrzejewska A, Dabrowska S, Lukomska B, Janowski M. Mesenchymal stem cells for neurological disorders. Adv Sci (Weinh) 2021; 8: 2002944-2002971.
33. Heydari MB, Ghanbari-Movahed Z, Heydari M, Farzaei MH. In vitro study of the mesenchymal stem cells-conditional media role in skin wound healing process: A systematic review. Int Wound J 2022; 19: 2210-2223.
34. Ren ZW, Zhou JG, Xiong ZK, Zhu FZ, Guo XD. Effect of exosomes derived from MiR-133b-modified ADSCs on the recovery of neurological function after SCI. Eur Rev Med Pharmacol Sci 2019; 23: 52-60.
35. Li C, Li X, Zhao B, Wang C. Exosomes derived from miR-544-modified mesenchymal stem cells promote recovery after spinal cord injury. Arch Physiol Biochem 2020; 126: 369-375.
36. Huang JH, Xu Y, Yin XM, Lin FY. Exosomes derived from miR-126-modified MSCs promote angiogenesis and neurogenesis and attenuate apoptosis after spinal cord injury in rats. Neuroscience 2020; 424: 133-145.